Liposome-delivered rebamipide as an add-on treatment for Staphylococcus aureus bacteremia
Official title: Drug Repurposing for the Treatment of Staphylococcus aureus Bacteremia
Funded at Cmtx Biotech, INC. · NIH-11314909 · Data updated 2026-11-12
A biotech company is testing a liposome-formulated rebamipide to help the body fight Staphylococcus aureus bloodstream infections alongside standard antibiotics.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Cmtx Biotech, INC. NIH-funded |
| Lab location | 1 site (Kings Park, United States) |
| Project start | September 1, 2026 |
| Project end | August 31, 2027 |
| Funding year | 2026 |
| Award (this year) | $296,470 |
| NIH project number | 1R41AI197642-01 |
| Project ID | NIH-11314909 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults with Staphylococcus aureus bacteremia who are candidates for adjunctive therapies and can participate in early-phase formulation and safety studies.
✕Less likely to help
Patients with non-Staphylococcus aureus infections or those unable to receive adjunctive host-directed therapies may not benefit.
What this research studies
This project aims to develop a new liposomal version of rebamipide to modulate the body’s response to Staphylococcus aureus bacteremia. It is a Phase I STTR focused on safety and feasibility in conjunction with existing antibiotics. The approach targets host-directed mechanisms to complement antimicrobial therapy, with plans to translate findings toward patients with serious bloodstream infections. The study will involve formulation development and early testing to assess delivery and potential clinical benefits in humans.
Why it matters
Potential benefit: If successful, patients with Staphylococcus aureus bloodstream infections could experience improved outcomes when combining this host-directed therapy with standard antibiotics.
How similar studies have gone: Phase I studies of host-modulatory approaches show potential, but this exact liposomal rebamipide strategy for SAB is novel and early-stage.
Where this research is happening
-
Cmtx Biotech, INC.
Kings Park, United States Active
Researchers
- Principal investigator: Carpino, Nicholas a — Cmtx Biotech, INC.
- Study coordinator: Carpino, Nicholas a
Related research
Other NIH-funded projects on the same topics.
-
Collaborative AI for safer, faster bacteremia care
A physician-centered AI system is being built to help diagnose and treat bloodstream infections more accurately and safely, with the goal of reducing sepsis deaths.
-
Rapid pathogen ID and antibiotic testing for bacteremia using immune capture, microfluidics, and AI
A fast, AI-assisted diagnostic system will identify bacteria in blood and determine which antibiotics are likely to work, helping doctors treat bacteremia sooner.
-
Predicting which febrile kids with sickle cell disease are at low risk for bacteremia
A small, patient-facing prediction rule is being developed to help doctors decide which febrile children with sickle cell disease really need aggressive testing and antibiotics.
-
Multimodal antibody therapy to treat Staphylococcus aureus bloodstream infections
A hospital-focused immunotherapy approach uses a mix of antibodies to help fight blood infections from Staphylococcus aureus by blocking immune evasion and bacterial growth.
-
Defining how macrophages fight Klebsiella in the blood
This grant studies how innate immune cells called macrophages protect against Klebsiella pneumoniae bloodstream infections to help reduce sepsis mortality.
-
Epigenomic clues and immune context in stubborn MRSA bloodstream infections
Researchers are studying why some MRSA bloodstream infections persist despite antibiotics and how the immune system and bacterial DNA packaging (epigenetics) influence this, with the goal of better treatments.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.